http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011113733-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-13 |
| filingDate | 2009-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011113733-A |
| titleOfInvention | Derivatives of 1-amino-alkylcyclohexane for the treatment of cognitive impairment in noise in the ears |
| abstract | 1. The use of a derivative of 1-amino-alkylcyclohexane for the manufacture of a medicament for the treatment or prevention of cognitive impairment associated with tinnitus. ! 2. The use according to claim 1, where the derivative of 1-amino-alkylcyclohexane is neramexane or its pharmaceutically acceptable salt. ! 3. The use according to claim 2, where the derivative of 1-amino-alkylcyclohexane is neramexane mesylate. ! 4. The use according to claim 3, where the drug is made for the introduction of neramexane mesylate in the range from about 5 mg to about 150 mg / day, in the range from about 5 mg to about 100 mg / day, in the range from about 5 mg to about 75 mg / day, at a dose of about 50 mg / day, or at a dose of about 75 mg / day. ! 5. The use according to any one of claims 2 to 4, wherein the drug is made to administer neramexane or its pharmaceutically acceptable salt once a day, twice a day (b.i.d.) or three times a day. ! 6. The use according to claim 5, where the drug is made for the introduction of neramexane or its pharmaceutically acceptable salt twice a day. ! 7. The use according to any one of claims 2 to 4, wherein the medicament is formulated to administer neramexane or a pharmaceutically acceptable salt thereof in an immediate release formulation or in a modified release formulation. ! 8. The use according to any one of claims 1 to 4, where the drug is made for the introduction of a derivative of 1-amino-alkylcyclohexane in combination with an additional pharmaceutical agent, which is shown to be effective in the treatment or prevention of cognitive impairment. ! 9. The use according to any one of claims 1 to 4, where |
| priorityDate | 2008-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 18.